Michelle Van Name, MD
Associate Professor of Pediatrics (Endocrinology)Cards
About
Research
Publications
2025
Pharmacokinetic Properties of Once‐Weekly Insulin Icodec in Children and Adolescents With Type 2 Diabetes
Van Name M, Ásbjörnsdóttir B, Gomes M, Hale P, Udupa K, Vinther S, Wolf R, Ribel-Madsen R. Pharmacokinetic Properties of Once‐Weekly Insulin Icodec in Children and Adolescents With Type 2 Diabetes. Pediatric Diabetes 2025, 2025 DOI: 10.1155/pedi/5514927.Peer-Reviewed Original ResearchGeometric mean total exposuresOnce-weekly administrationAdverse eventsType 2 diabetesSingle doseBasal insulinMedian time to maximum concentrationSingle-dose pharmacokinetic profileInsulin icodecPharmacokinetic profilePharmacokinetic propertiesMedian t-maxTime to maximum concentrationSevere adverse eventsInjection site reactionsDosing intervalSite reactionsOnce-weeklyPharmacokinetic analysisInsulin-treatedDays postinjectionSubcutaneous injectionHyperglycemic episodesMaximum concentrationIcodec
2024
Type 1 Diabetes in Children and Adolescents
Hu P, Van Name M, Stephenson K, Sikes K, Tamborlane W. Type 1 Diabetes in Children and Adolescents. 2024, 809-835. DOI: 10.1007/978-3-031-66296-6_30.Peer-Reviewed Original ResearchType 1 diabetesRelative insufficiency of insulinContinuous glucose monitoringMacrovascular complications of diabetesDevelopment of diabetes-related complicationsComplications of diabetesInsufficiency of insulinAdvanced diabetes technologiesPediatric patientsMetabolic derangementsTherapeutic advancesDiabetes mellitusDiabetes-related complicationsMacrovascular complicationsControl of T1DReal-time continuous glucose monitoringMetabolic controlDiabetesLifelong disorderRelative insufficiencyDaily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity
Barbieri E, Bonet J, Fox D, Nelson R, Nelson M, Nelson L, Fernandez C, Van Name M, Samuels S, Caprio S, Sabati M, Galderisi A, Sherr J, Man C, Santoro N. Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity. Obesity 2024, 33: 116-124. PMID: 39658509, PMCID: PMC11666407, DOI: 10.1002/oby.24175.Peer-Reviewed Original ResearchConceptsIntrahepatic fat contentDaily glucose variabilityLiver proton density fat fractionProton density fat fractionGlucose variabilityInsulin sensitivityOral glucose tolerance testFat fractionInsulin secretionAssociated with insulin resistanceFirst-phase insulin secretionAssociated with 2-h glucoseGlucose tolerance testGlucose standard deviationMagnetic resonance imagingOral minimal modelCoefficient of variationBasal insulin secretionPediatric obesityPostprandial glucoseTolerance testCell sensitivityInsulin resistanceObesityResonance imagingClinical Characteristics of Offspring Born to Parents with Type 2 Diabetes Diagnosed in Youth: Observations from TODAY
Tryggestad J, Kelsey M, Drews K, Zhou S, Chang N, Escaname E, Gidding S, Isganaitis E, McKay S, Shah R, Van Name M. Clinical Characteristics of Offspring Born to Parents with Type 2 Diabetes Diagnosed in Youth: Observations from TODAY. Children 2024, 11: 630. PMID: 38929210, PMCID: PMC11201816, DOI: 10.3390/children11060630.Peer-Reviewed Original ResearchType 2 diabetesDiabetes exposureMarker of overall healthPrimary care providersOffspring of participantsLower household incomeDaily medication useYouth-onset type 2 diabetesSignificant socioeconomic disadvantageParent self-reportCare providersSocioeconomic disadvantageHealth outcomesYears of ageMedication useOverall healthRisk of healthSelf-reportEducational disparitiesHousehold incomeParent reportFemale participantsHealthParticipantsRates of recidivismSafety and prescribing recommendations for verapamil in newly diagnosed pediatric type 1 diabetes (T1D): The CLVer experience
Ekhlaspour L, Buckingham B, Bauza C, Clements M, Forlenza G, Neyman A, Norlander L, Schamberger M, Sherr J, Bailey R, Beck R, Kollman C, Beasley S, Cobry E, DiMeglio L, Paprocki E, Van Name M, Moran A, Group F. Safety and prescribing recommendations for verapamil in newly diagnosed pediatric type 1 diabetes (T1D): The CLVer experience. Journal Of Clinical & Translational Endocrinology 2024, 36: 100352. PMID: 38860154, PMCID: PMC11163172, DOI: 10.1016/j.jcte.2024.100352.Peer-Reviewed Original ResearchSide effectsDiabetes care teamRate of adverse eventsTreated with placeboLiver function abnormalitiesBeta-cell preservationPediatric type 1 diabetesComplete AV blockObservational extension studyAsymptomatic ECG changesPotential side effectsSide effect monitoringCare teamType 1 diabetesPlacebo groupStudy drugVerapamil doseFull dosageNewly-diagnosedAdverse eventsAV blockDrug doseECG changesStudy endFunctional abnormalitiesReal‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
Samuels S, Chajecki A, Hu P, Kayser M, Weyman K, Pan B, Brown E, Van Name M, Wolf R. Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c. Diabetes Obesity And Metabolism 2024, 26: 1305-1313. PMID: 38229444, DOI: 10.1111/dom.15430.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RAFollow-upType 2 diabetesReceptor agonistsGLP-1RAsDiverse cohort of youthEffects of glucagon-like peptide-1 receptor agonistsBody mass index z-scoreMedian follow-upMulticentre retrospective studyReduced insulin doseGLP-1RA treatmentPatients prescribed insulinFollow-up visitAssociated with short-term improvementsPaediatric diabetes centresManagement of type 2 diabetesManagement of T2DMetformin regimenBMI-zMedian HbA1cRetrospective studyDosing frequency
2023
Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity
Galderisi A, Tricò D, Lat J, Samuels S, Weiss R, Van Name M, Pierpont B, Santoro N, Caprio S. Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity. JCI Insight 2023, 8: e165709. PMID: 37847560, PMCID: PMC10721315, DOI: 10.1172/jci.insight.165709.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testΒ-cell functionIncretin effectBeta-cell functionInsulin sensitivityInsulin secretionGlucose levelsCell functionIsoglycemic intravenous glucose infusionGreater insulin sensitivityIntravenous glucose infusionPubertal transitionGlucose tolerance testGLP-17Glucagon suppressionGlucose infusionObesityLongitudinal increaseBaselineOGTTEffect groupGreater increaseLongitudinal trajectoriesSecretionGroupMaternal diabetes in youth-onset type 2 diabetes is associated with progressive dysglycemia and risk of complications
RD S, SD C, L E, ME G, J K, MM K, R F, B T, JB T, M V, E I. Maternal diabetes in youth-onset type 2 diabetes is associated with progressive dysglycemia and risk of complications. 2023 DOI: 10.1530/ey.20.10.7.Peer-Reviewed Original Research1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis
SAMUELS S, CHAJECKI A, HU P, KAYSER M, WEYMAN K, PAN B, BROWN E, VAN NAME M, WOLF R. 1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis. Diabetes 2023, 72 DOI: 10.2337/db23-1100-p.Peer-Reviewed Original ResearchGlucagon-like-peptide-1 agonistsFollow-upAmerican Diabetes AssociationType 2 diabetesManagement of T2DDiverse cohort of youthReduced doses of insulinMonths of follow-upMulticenter retrospective analysisGlucagon-like-peptide-1High risk of diabetic complicationsGLP-1 agonistsRisk of diabetic complicationsDoses of insulinPediatric diabetes centersBaseline to follow-upAssociated with improvementsMetformin usePharmacological optionsReduced dosePediatric populationPrandial insulinPrescribed metforminRetrospective analysisNational Institutes of HealthDecreased Bone Density and Strength in Young People After Bariatric Surgery: How Much Matters?
Hornick M, Van Name M. Decreased Bone Density and Strength in Young People After Bariatric Surgery: How Much Matters? Journal Of Bone And Mineral Research 2023, 38: 931-932. PMID: 37314023, DOI: 10.1002/jbmr.4831.Commentaries, Editorials and Letters
Clinical Trials
Current Trials
Metabolic Changes Induced by a Very Low Carbohydrate Diet in Youth With Type 1 Diabetes
HIC ID2000029479RoleSub InvestigatorPrimary Completion Date11/15/2024Recruiting ParticipantsGenderBothAge12 years - 24 yearsPathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Youth with Obesity
HIC ID2000028731RoleSub InvestigatorPrimary Completion Date08/31/2025Recruiting ParticipantsGenderBothAge12 years - 22 yearsThe Role of Hepatic De Novo Lipogenesis (DNL) in the Pathogenesis of Hepatic Steatosis
HIC ID1604017607RoleSub InvestigatorPrimary Completion Date05/01/2023Recruiting ParticipantsGenderBothAge12 years - 30 yearsStudy to investigate adipocyte cell and lipid turnover in obese adolescents
HIC ID1503015459RoleSub InvestigatorPrimary Completion Date05/01/2025Recruiting ParticipantsGenderBothAge12 years - 21 yearsPrevalence of Carbohydrate Intolerance in Lean and Obese Children
HIC ID9909011190RoleSub InvestigatorPrimary Completion Date09/30/2025Recruiting ParticipantsGenderBothAge8 years - 18 years
Clinical Care
Overview
Michelle Van Name, MD, is a pediatric endocrinologist who specializes in treating children with obesity, type 1 diabetes and type 2 diabetes. Dr. Van Name was drawn to pediatric medicine because she enjoys teaching children how they can improve their health.
“A lot of teaching goes into working with my patients. We talk about causes and effects and come up with ways to get healthier,” she says, adding that for patients with obesity or type 2 diabetes, she explains the importance of genetics in developing these conditions. “For all my patients, I try to identify treatment strategies that will fit into their lives and partner with them and their families to make these a reality that will carry into adulthood.”
Dr. Van Name also treats adolescents who are interested in sleeve gastrectomy, a type of bariatric surgery for weight loss. “When behavioral and lifestyle modifications aren’t enough to treat obesity and obesity-related medical problems, we consider bariatric surgery. Along with the patient and family, our multidisciplinary team weighs the potential benefits of surgery and improved health in adulthood with the risks,” she says.
As an assistant professor of pediatrics (endocrinology) at Yale School of Medicine, Dr. Van Name’s is an active researcher, including work to see if medications approved for adults to treat type 2 diabetes can be used in adolescents. Her research also focuses on use of technologies and non-insulin medications for patients with type 1 diabetes.
“I am fortunate to work with a wonderful team at Yale, who have been at the forefront of research leading to improvements to manage type 1 diabetes and decrease the burden on patients and parents,” she says. “We have seen an increase in obesity in individuals with type 1 diabetes, and my research focuses on this as well.”
Clinical Specialties
Fact Sheets
Diabetes: Symptoms, Causes, and Treatments
Learn More on Yale MedicineType 1 Diabetes: Symptoms, Causes, and Treatments
Learn More on Yale MedicineType 2 Diabetes: Symptoms and Treatments
Learn More on Yale MedicineHemoglobin A1C Test
Learn More on Yale Medicine
Yale Medicine News
News
News
- April 22, 2024Source: diaTRIBE
Type 1 on a GLP-1 Drug? Watch for Hypoglycemia and DKA
- March 06, 2024
New Frontiers in Obesity Research at Yale
- November 09, 2023Source: Yale Daily News
Yale researchers reflect on adolescent bariatric surgery
- November 01, 2023
The next era of obesity medicine
Get In Touch
Contacts
Pediatric Endocrinology & Diabetes
P.O. Box 208064
New Haven, CT 06520
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.